tradingkey.logo
tradingkey.logo
Search

Daxor Corp

DXR
Add to Watchlist
10.750USD
-0.510-4.51%
Close 05/15, 16:00ETQuotes delayed by 15 min
62.64MMarket Cap
30.92P/E TTM

More Details of Daxor Corp Company

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Daxor Corp Info

Ticker SymbolDXR
Company nameDaxor Corp
IPO dateJul 25, 1983
CEOFeldschuh (Michael Richard)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJul 25
AddressSuite 7120
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10118
Phone12122440555
Websitehttps://www.daxor.com/
Ticker SymbolDXR
IPO dateJul 25, 1983
CEOFeldschuh (Michael Richard)

Company Executives of Daxor Corp

Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
+0.47%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
+33.39%
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
+4.75%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--
Mr. Bret Shapiro
Mr. Bret Shapiro
IR Contact Officer
IR Contact Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
+0.47%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
+33.39%
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
+4.75%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Joseph Feldschuh UEO
43.82%
Feldschuh (Michael Richard)
3.67%
Feldschuh (Jonathan Adam)
0.93%
Vanguard Capital Management, LLC
0.83%
Renaissance Technologies LLC
0.48%
Other
50.28%
Shareholders
Shareholders
Proportion
Joseph Feldschuh UEO
43.82%
Feldschuh (Michael Richard)
3.67%
Feldschuh (Jonathan Adam)
0.93%
Vanguard Capital Management, LLC
0.83%
Renaissance Technologies LLC
0.48%
Other
50.28%
Shareholder Types
Shareholders
Proportion
Individual Investor
49.03%
Investment Advisor
1.53%
Hedge Fund
0.48%
Research Firm
0.05%
Other
48.90%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
16
120.43K
2.07%
+11.27K
2025Q4
14
102.17K
2.33%
--
2025Q3
14
102.17K
2.33%
+2.08K
2025Q2
15
100.09K
2.26%
+3.04K
2025Q1
15
97.05K
2.30%
-16.23K
2024Q4
15
106.77K
1.91%
+12.72K
2024Q3
14
94.05K
1.85%
+4.76K
2024Q2
13
89.28K
1.77%
+4.12K
2024Q1
13
85.17K
1.54%
+11.30K
2023Q4
13
73.17K
1.98%
-131.00
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Joseph Feldschuh UEO
2.55M
43.82%
--
--
Dec 16, 2025
Feldschuh (Michael Richard)
212.69K
3.65%
--
--
Dec 16, 2025
Feldschuh (Jonathan Adam)
53.91K
0.93%
+18.00K
+50.13%
Dec 16, 2025
Renaissance Technologies LLC
28.22K
0.48%
-700.00
-2.42%
Dec 31, 2025
Michel (Robert J)
21.05K
0.36%
+1.00K
+4.99%
Mar 31, 2026
Jefferies (John M.D.)
10.93K
0.19%
+5.94K
+119.06%
Mar 20, 2026
Morgan Stanley Smith Barney LLC
3.24K
0.06%
-300.00
-8.48%
Dec 31, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI